This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Psoriatic Arthritis
and you are
between 18 and 89
years old
-
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

Biologics such as anti-Tumor Necrosis Factor or TNF inhibitor (TNFi) for treatment of Psoriatic Arthritis (PsA) has greatly reduced bone damage. This collaborative study will provide insights into key mechanisms that underlie inflammatory arthritis and bone damage in psoriatic joints and will catalyze biomarker discovery, identifying early biologic responders to facilitate optimization of therapy.
Tris trial is registered with FDA with number: NCT02413749. The sponsor of the trial is University of Rochester and it is looking for 68 volunteers for the current phase.
Official trial title:
DC-STAMP and TRAF3: Regulators of Osteoclastogenesis and Biomarkers in Psoriatic Arthritis